Abstract
CYP24A1 mutations are now accepted as a cause of idiopathic infantile hypercalcemia (IIH). A rapid liquid-chromatography tandem mass spectrometry (LC-MS/MS)-based blood test enabling measurement of the 25-OH-D3:24,25-(OH)2D3 ratio (R) can identify IIH patients on the basis of reduced C24-hydroxylation of 25-OH-D3 by CYP24A1 in vivo. Although values of this ratio are significantly elevated in IIH, somewhat surprisingly, serum 24,25-(OH)2D3 remains detectable. The current study explores possible explanations for this including: residual CYP24A1 enzyme activity in individuals with certain CYP24A1 genotypes, expression of alternative C24-hydroxylases, and the possibility of isobaric contamination of the 24,25-(OH)2D3 peak on LC-MS/MS. We employed an extended 20-min run time on LC-MS/MS to study serum vitamin D metabolites in patients with IIH due to mutations of CYP24A1 or SLC34A1; in unaffected heterozygotes and dialysis patients; in patients with vitamin D deficiency; as well as in normal subjects exhibiting a broad range of 25-OH-D levels. We identified 25,26-(OH)2D3 as a contaminant of the 24,25-(OH)2D3 peak. In normals, the concentration of 24,25-(OH)2D3 greatly exceeds 25,26-(OH)2D3; however, 25,26-(OH)2D3 becomes more significant in IIH with CYP24A1 mutations and in dialysis patients, where 24,25-(OH)2D3 levels are low when CYP24A1 function is compromised. Mean R in 30 IIH-CYP24A1 patients was 700 (range, 166 to 2168; cutoff=140) as compared with 31 in 163 controls. Furthermore, patients possessing CYP24A1 L409S alleles exhibited higher 24,25-(OH)2D3 levels and lower R (mean R=268; n=8) than patients with other mutations. We conclude that a chromatographic approach which resolves 24,25-(OH)2D3 from 25,26-(OH)2D3 produces a more accurate R that can be used to differentiate pathological states where CYP24A1 activity is altered. The origin of the residual serum 24,25-(OH)2D3 in IIH patients appears to be multifactorial.
| Original language | English (US) |
|---|---|
| Journal | Journal of Bone and Mineral Research |
| DOIs | |
| State | Accepted/In press - 2017 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Endocrinology, Diabetes and Metabolism
- Orthopedics and Sports Medicine
Cite this
Improved Screening Test for Idiopathic Infantile Hypercalcemia Confirms Residual Levels of Serum 24,25-(OH)2D3 in Affected Patients. / Kaufmann, Martin; Morse, Nicole; Molloy, Billy Joe; Cooper, Donald P.; Schlingmann, Karl Peter; Molin, Arnaud; Kottler, Marie Laure; Gallagher, John Christopher G.; Armas, Laura; Jones, Glenville.
In: Journal of Bone and Mineral Research, 2017.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Improved Screening Test for Idiopathic Infantile Hypercalcemia Confirms Residual Levels of Serum 24,25-(OH)2D3 in Affected Patients
AU - Kaufmann, Martin
AU - Morse, Nicole
AU - Molloy, Billy Joe
AU - Cooper, Donald P.
AU - Schlingmann, Karl Peter
AU - Molin, Arnaud
AU - Kottler, Marie Laure
AU - Gallagher, John Christopher G.
AU - Armas, Laura
AU - Jones, Glenville
PY - 2017
Y1 - 2017
N2 - CYP24A1 mutations are now accepted as a cause of idiopathic infantile hypercalcemia (IIH). A rapid liquid-chromatography tandem mass spectrometry (LC-MS/MS)-based blood test enabling measurement of the 25-OH-D3:24,25-(OH)2D3 ratio (R) can identify IIH patients on the basis of reduced C24-hydroxylation of 25-OH-D3 by CYP24A1 in vivo. Although values of this ratio are significantly elevated in IIH, somewhat surprisingly, serum 24,25-(OH)2D3 remains detectable. The current study explores possible explanations for this including: residual CYP24A1 enzyme activity in individuals with certain CYP24A1 genotypes, expression of alternative C24-hydroxylases, and the possibility of isobaric contamination of the 24,25-(OH)2D3 peak on LC-MS/MS. We employed an extended 20-min run time on LC-MS/MS to study serum vitamin D metabolites in patients with IIH due to mutations of CYP24A1 or SLC34A1; in unaffected heterozygotes and dialysis patients; in patients with vitamin D deficiency; as well as in normal subjects exhibiting a broad range of 25-OH-D levels. We identified 25,26-(OH)2D3 as a contaminant of the 24,25-(OH)2D3 peak. In normals, the concentration of 24,25-(OH)2D3 greatly exceeds 25,26-(OH)2D3; however, 25,26-(OH)2D3 becomes more significant in IIH with CYP24A1 mutations and in dialysis patients, where 24,25-(OH)2D3 levels are low when CYP24A1 function is compromised. Mean R in 30 IIH-CYP24A1 patients was 700 (range, 166 to 2168; cutoff=140) as compared with 31 in 163 controls. Furthermore, patients possessing CYP24A1 L409S alleles exhibited higher 24,25-(OH)2D3 levels and lower R (mean R=268; n=8) than patients with other mutations. We conclude that a chromatographic approach which resolves 24,25-(OH)2D3 from 25,26-(OH)2D3 produces a more accurate R that can be used to differentiate pathological states where CYP24A1 activity is altered. The origin of the residual serum 24,25-(OH)2D3 in IIH patients appears to be multifactorial.
AB - CYP24A1 mutations are now accepted as a cause of idiopathic infantile hypercalcemia (IIH). A rapid liquid-chromatography tandem mass spectrometry (LC-MS/MS)-based blood test enabling measurement of the 25-OH-D3:24,25-(OH)2D3 ratio (R) can identify IIH patients on the basis of reduced C24-hydroxylation of 25-OH-D3 by CYP24A1 in vivo. Although values of this ratio are significantly elevated in IIH, somewhat surprisingly, serum 24,25-(OH)2D3 remains detectable. The current study explores possible explanations for this including: residual CYP24A1 enzyme activity in individuals with certain CYP24A1 genotypes, expression of alternative C24-hydroxylases, and the possibility of isobaric contamination of the 24,25-(OH)2D3 peak on LC-MS/MS. We employed an extended 20-min run time on LC-MS/MS to study serum vitamin D metabolites in patients with IIH due to mutations of CYP24A1 or SLC34A1; in unaffected heterozygotes and dialysis patients; in patients with vitamin D deficiency; as well as in normal subjects exhibiting a broad range of 25-OH-D levels. We identified 25,26-(OH)2D3 as a contaminant of the 24,25-(OH)2D3 peak. In normals, the concentration of 24,25-(OH)2D3 greatly exceeds 25,26-(OH)2D3; however, 25,26-(OH)2D3 becomes more significant in IIH with CYP24A1 mutations and in dialysis patients, where 24,25-(OH)2D3 levels are low when CYP24A1 function is compromised. Mean R in 30 IIH-CYP24A1 patients was 700 (range, 166 to 2168; cutoff=140) as compared with 31 in 163 controls. Furthermore, patients possessing CYP24A1 L409S alleles exhibited higher 24,25-(OH)2D3 levels and lower R (mean R=268; n=8) than patients with other mutations. We conclude that a chromatographic approach which resolves 24,25-(OH)2D3 from 25,26-(OH)2D3 produces a more accurate R that can be used to differentiate pathological states where CYP24A1 activity is altered. The origin of the residual serum 24,25-(OH)2D3 in IIH patients appears to be multifactorial.
UR - http://www.scopus.com/inward/record.url?scp=85018631394&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018631394&partnerID=8YFLogxK
U2 - 10.1002/jbmr.3135
DO - 10.1002/jbmr.3135
M3 - Article
C2 - 28304097
AN - SCOPUS:85018631394
JO - Journal of Bone and Mineral Research
JF - Journal of Bone and Mineral Research
SN - 0884-0431
ER -